BIOMAT Database Logo BIOMAT Database Logo

Increased interleukin-36γ expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/Sézary syndrome. 2018

Sayaka Otobe, and Makoto Sugaya, and Rina Nakajima, and Tomonori Oka, and Naomi Takahashi, and Miyoko Kabasawa, and Tomomitsu Miyagaki, and Yoshihide Asano, and Shinichi Sato
Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.

Interleukin (IL)-36γ is expressed by keratinocytes and functions as a key initiator of inflammation in the skin. IL-36γ expression is enhanced by tumor necrosis factor-α and IL-17A, having a strong association with psoriasis. In this study, we examined the role of IL-36γ in atopic dermatitis (AD) and mycosis fungoides (MF)/Sézary syndrome (SS). Serum levels of IL-36γ in AD patients and MF/SS patients were elevated compared with those of healthy controls. Importantly, serum IL-36γ levels in AD patients positively correlated with Eczema Area and Severity Index and those of MF/SS patients positively correlated with serum soluble IL-2 receptor levels. IL-36γ mRNA levels in AD skin and MF/SS skin were significantly higher than those of normal skin. IL-36γ mRNA levels in MF/SS skin positively correlated with IL-17A mRNA levels. Immunohistochemical staining revealed that IL-36γ was highly expressed in keratinocytes in lesional skin of AD and MF/SS. Taken together, our study demonstrated that IL-36γ expression was increased in sera and skin of patients with AD and MF/SS as was reported in psoriatic patients.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009182 Mycosis Fungoides A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.
D003876 Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema. Eczema, Atopic,Eczema, Infantile,Neurodermatitis, Atopic,Neurodermatitis, Disseminated,Atopic Dermatitis,Atopic Eczema,Atopic Neurodermatitis,Disseminated Neurodermatitis,Infantile Eczema
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated

Related Publications

Sayaka Otobe, and Makoto Sugaya, and Rina Nakajima, and Tomonori Oka, and Naomi Takahashi, and Miyoko Kabasawa, and Tomomitsu Miyagaki, and Yoshihide Asano, and Shinichi Sato
Abnormal expression of interleukin-23 in mycosis fungoides/Sézary syndrome lesions.
December 2006, Archives of dermatological research,
Sayaka Otobe, and Makoto Sugaya, and Rina Nakajima, and Tomonori Oka, and Naomi Takahashi, and Miyoko Kabasawa, and Tomomitsu Miyagaki, and Yoshihide Asano, and Shinichi Sato
Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome.
May 2012, Journal of cutaneous pathology,
Sayaka Otobe, and Makoto Sugaya, and Rina Nakajima, and Tomonori Oka, and Naomi Takahashi, and Miyoko Kabasawa, and Tomomitsu Miyagaki, and Yoshihide Asano, and Shinichi Sato
Mycosis fungoides and Sézary syndrome.
March 2008, Lancet (London, England),
Sayaka Otobe, and Makoto Sugaya, and Rina Nakajima, and Tomonori Oka, and Naomi Takahashi, and Miyoko Kabasawa, and Tomomitsu Miyagaki, and Yoshihide Asano, and Shinichi Sato
Mycosis fungoides and Sézary syndrome.
January 2013, Methods in molecular biology (Clifton, N.J.),
Sayaka Otobe, and Makoto Sugaya, and Rina Nakajima, and Tomonori Oka, and Naomi Takahashi, and Miyoko Kabasawa, and Tomomitsu Miyagaki, and Yoshihide Asano, and Shinichi Sato
[Sézary syndrome and mycosis fungoides].
January 1977, Nihon rinsho. Japanese journal of clinical medicine,
Sayaka Otobe, and Makoto Sugaya, and Rina Nakajima, and Tomonori Oka, and Naomi Takahashi, and Miyoko Kabasawa, and Tomomitsu Miyagaki, and Yoshihide Asano, and Shinichi Sato
Mycosis fungoides and Sézary syndrome.
September 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG,
Sayaka Otobe, and Makoto Sugaya, and Rina Nakajima, and Tomonori Oka, and Naomi Takahashi, and Miyoko Kabasawa, and Tomomitsu Miyagaki, and Yoshihide Asano, and Shinichi Sato
Mycosis fungoides and Sézary syndrome.
April 1981, Pathology, research and practice,
Sayaka Otobe, and Makoto Sugaya, and Rina Nakajima, and Tomonori Oka, and Naomi Takahashi, and Miyoko Kabasawa, and Tomomitsu Miyagaki, and Yoshihide Asano, and Shinichi Sato
Mycosis fungoides and Sézary syndrome.
April 2023, Blood research,
Sayaka Otobe, and Makoto Sugaya, and Rina Nakajima, and Tomonori Oka, and Naomi Takahashi, and Miyoko Kabasawa, and Tomomitsu Miyagaki, and Yoshihide Asano, and Shinichi Sato
Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
May 2001, The British journal of dermatology,
Sayaka Otobe, and Makoto Sugaya, and Rina Nakajima, and Tomonori Oka, and Naomi Takahashi, and Miyoko Kabasawa, and Tomomitsu Miyagaki, and Yoshihide Asano, and Shinichi Sato
Increased serum neopterin levels in mycosis fungoides and Sézary syndrome.
December 1999, The British journal of dermatology,
Copied contents to your clipboard!